Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Chief Executive Officer Appointment
The Board of Directors (the "Board") of Viridian Therapeutics, Inc., formerly
known as Miragen Therapeutics, Inc. (the "Company"), appointed Jonathan Violin,
Ph.D., M.B.A. as Chief Executive Officer and Principal Executive Officer of the
Company, effective as of January 15, 2021.
Dr. Violin's appointment follows the resignation of Lee Rauch from her position
as Chief Executive Officer (and Principal Executive Officer) and as a member of
the Board. The resignation of Ms. Rauch was effective as of January 15, 2021.
The Company has entered into a Separation and Release Agreement ("Separation
Agreement") with Ms. Rauch effective January 15, 2021. Pursuant to the terms of
her Separation Agreement, Ms. Rauch will be entitled to receive the following
severance benefits: (i) payment of 18 months of Ms. Rauch's current base salary,
(ii) a one-time payment of $541,000 to be paid immediately following the
effectiveness of the general release described below, (iii) accelerated vesting
of all unvested and outstanding stock options previously awarded to Ms. Rauch,
and (iv) payment of Ms. Rauch's COBRA premiums for up to 18 months. The payment
of the foregoing benefits under the Separation Agreement is conditioned upon the
effectiveness of a general release in favor of the Company. Additionally,
pursuant to the terms of her Separation Agreement, Ms. Rauch will be entitled to
receive 100% of her target bonus for 2020 (which is equal to $270,500) as and
when such bonuses are paid in 2021.
Following her separation from the Company, Ms. Rauch will serve as a consultant
to the Company. The initial term of the consultant arrangement will be three
months, unless mutually extended. In exchange for providing consulting services,
Ms. Rauch will receive a consulting fee of $45,000 per month during the term of
the consulting agreement. On January 18, 2021, Ms. Rauch was also awarded an
option to purchase up to 15,000 shares of the Company's common stock, par value
$0.01 per share ("Common Stock") with an exercise price of $23.03 per share. The
option vests and becomes exercisable ratably over six months. Upon termination
of her consulting services, Ms. Rauch will have a period of 12 months to
exercise the vested options.
Ms. Rauch's resignation from the Board was not the result of any disagreements
with the Company relating to the Company's operations, policies or practices.
In connection with his appointment as Chief Executive Officer, Dr. Violin
entered into a new employment agreement with Viridian and resigned from his role
as Chief Operating Officer. Pursuant to the terms of his employment agreement,
Dr. Violin is entitled to an annual base salary of $567,000 and an annual target
bonus equal to 60% of his base salary. On January 18, 2021, Dr. Violin was also
awarded an option to purchase up to 800,075 shares Common Stock, with an
exercise price of $23.03 per share, equal to the last reported closing price of
the Common Stock on the Nasdaq Global Market prior to the grant. This option
vests and becomes exercisable on a ratable monthly basis over a four-year period
from the date of grant. If Dr. Violin's employment is terminated by the Company
without "cause" or he resigns for "good reason" (each, as defined in the
agreement) or due to death or by disability (collectively, "Involuntary
Termination"), Dr. Violin will, subject to the execution of a release in favor
of the Company, be entitled to receive: (i) an amount equal to twelve months of
base salary, (ii) credit for an additional twelve months of vesting under all
outstanding equity awards that are subject to time-based vesting criteria, and
(iii) up to twelve months of health insurance reimbursement under COBRA. In the
event of Dr. Violin's Involuntary Termination within one month before or twelve
months after a change in control of the Company, Dr. Violin will instead be
entitled to receive the foregoing benefits, provided that all equity awards
subject to time-based vesting criteria will accelerate full.
The foregoing descriptions of the employment agreements and severance agreement
are not complete and are qualified in their entirety by reference to the
employment agreements and severance agreement, each of which is filed herewith
as Exhibits 10.1 and 10.2, respectively and incorporated by reference herein.

--------------------------------------------------------------------------------

Chief Medical Officer Appointment
The Board appointed Barrett Katz, MD, M.B.A. as Chief Medical Officer of the
Company, effective as of January 18, 2021. Prior to becoming Chief Medical
Officer, Dr. Katz was the President and Chief Medical Officer of the Retinagenix
and Fortify subsidiaries of BridgeBio Pharma, Inc. from June 2019 through
October 2020. Previously, Dr. Katz served as the Chief Medical Officer of
GenSight Biologics with oversight for their gene therapy programs in
Ophthalmology. Prior to that, he served as the DeJur Chair of Ophthalmology and
Professor of Ophthalmology, Neurology and Neurosurgery at Montefiore Medical
Center and the Albert Einstein College of Medicine in New York from 2010 until
2017. Before joining Montefiore and the Albert Einstein College of Medicine, Dr.
Katz had been engaged in the biotech industry and drug development space for
several years. He served as Chief Executive Officer of Danube Pharmaceuticals,
Chief Medical Officer of Fovea Pharmaceuticals and Vice President of Medical
Affairs and Strategy at Eyetech. Before moving to industry, he had a
distinguished career in academia and served as co-director of a joint fellowship
in ophthalmologic drug development co-sponsored by The George Washington
University and the U.S. Food and Drug Administration. Dr. Katz received his
medical degree from Case-Western Reserve University School of Medicine. He
completed an internship in Internal Medicine at Parkland Hospital in Dallas,
served as a research staff associate in Neuro-Virology at the National
Institutes of Health, and completed residencies at Harvard University and
Tufts-New England Medical Center in both Neurology and Ophthalmology,
respectively. He completed fellowships at Harvard and the University of
California, San Francisco (UCSF). Dr. Katz obtained an M.B.A. from the
University of Rochester's Simon School of Business and has served on the
faculties of the University of California at San Diego and San Francisco, the
University of Rochester, Cornell University and New York University.
Director Appointment
In connection with Dr. Violin's appointment as Chief Executive Officer and
Principal Executive Officer, he was also appointed as a director, effective as
of January 15, 2021. Dr. Violin has no family relationship with any of the
executive officers or directors of the Company. There are no arrangements or
understandings between Dr. Violin and any other person pursuant to which he was
appointed as an officer and director of the Company.
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal
Year.
Effective as of January 20, 2021, the Company amended its Certificate of
Incorporation (as amended, the "Certificate of Incorporation") to effect a
change of the Company's name from "Miragen Therapeutics, Inc." to "Viridian
Therapeutics, Inc." (the "Name Change").
The Board approved the Name Change pursuant to Section 242 of the General
Corporation Law of the State of Delaware. The Name Change does not affect the
rights of the Company's stockholders and there were no other changes to the
Certificate of Incorporation. A copy of the Certificate of Amendment filed with
the Secretary of State of the State of Delaware to affect the Name Change is
attached hereto as Exhibit 3.1 and incorporated herein by reference.
In connection with the Name Change, the Board also approved a restatement of the
Certificate of Incorporation to reflect all the certificate of amendments,
including the Certificate of Amendment, to the Certificate of Incorporation (the
"Restated Certificate of Incorporation") effective as of January 20, 2021. A
copy of the Restated Certificate of Incorporation is attached hereto as Exhibit
3.2 and incorporated herein by reference.
In connection with the Name Change, the Board also approved an amendment and
restatement of the Company's Amended and Restated Bylaws (as amended, the "Old
Bylaws") to reflect the Name Change (as amended and restated, the "Amended and
Restated Bylaws") effective as of January 20, 2021. There were no other changes
to the Old Bylaws. A copy of the Amended and Restated Bylaws is attached hereto
as Exhibit 3.3 and incorporated herein by reference.

--------------------------------------------------------------------------------


Item 8.01 Other Events.
In connection with the Name Change, the Company's ticker symbol changed to
"VRDN" from "MGEN". Trading under the new ticker symbol begins on January 20,
2021. The new CUSIP number for the Company's Common Stock is 92790C104.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.            Description

3.1                      Certificate of Amendment to the Restated

Certificate of Incorporation of the


                       Company, effective as of January 20, 2021.
3.2                      Restated Certificate of Incorporation of the

Company, effective as of January 20,


                       2021.
3.3                      Amended and Restated Bylaws of the Company, effective as of January 20, 2021.
10.1                     Employment Agreement by and between the Company

and Jonathan Violin, dated as of

January 15, 2021.
10.2                     Separation and Release Agreement by and between

the Company and Lee Rauch, dated


                       as of January 15, 2020.



                                     * * *

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses